Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of Bmab 1200 Autoinjector vs Prefilled Syringe in Healthy Subjects
NCT06738277Phase 1Completed
- Sponsor
- Biocon
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Starjemza in plaque psoriasis (2 arms), sponsored by Biocon. Primary endpoints: Maximum Observed Serum Concentration at Week 16 and Area Under the Concentration-Time Curve From Time Zero to Infinity at Week 16. Started Jan 2025; status: completed.
02
Drugs
Starjemza
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06738277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738277.